Exploration of Neuroscience

Table 1

Pharmacologic agents show effect through the melatonergic system

Pharmacologic agent	Mechanism of action	Approved indications	Research areas	References
Ramelteon	MT1 and MT2 agonism	Insomnia	Alzheimer’s disease Delirium Cancer	[94–106]
Agomelatine	MT1 and MT2 agonism 5HT2C antagonism	Major depressive disorder	Anxiety disordersAlzheimer’s disease Cancer Endothelial dysfunction	[107–133]
Tasimelteon	MT1 and MT2 agonism SCN pacemaker regulation	Non-24-h sleep-wake disorder	Alzheimer’s disease Sleep quality Jet lag	[134–136]
Neu-P11/Piromelatine	MT1 and MT2 receptor agonism 5HT1A/1D receptor agonism	None	Sleep disorders Depression Anxiety Alzheimer’s disease Insulin resistance type 2 diabetes	[137–145]
M6B, M7C	MT1 and MT2 agonism	None	Panic disorders Epilepsy	[139, 146]
UCM765	Selective MT2 agonism	None	Non-REM sleep disorders Anxiety	[137, 147, 148]
TIK-301	MT1 and MT2 agonism 5HT2B/5HT2C antagonism	Orphan drug status for circadian rhythm sleep disorders in blind individuals without retinal light exposure	Depression Epilepsy	[139, 149]